Interaction between influenza virus and Streptococcus pneumoniae in severe pneumonia

Expert Review of Respiratory Medicine

Volumn 2, Issue 5, 2008, Pages 663-672

  Madhi, Shabir A ^a,b,e   Schoub, Barry ^c   Klugman, Keith P ^d  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^d EMORY UNIVERSITY   (United States)

^e SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

Author keywords

Epidemiology; Influenza epidemic; Influenza virus; Pandemic influenza; Pneumonia; Prevention; Streptococcus pneumonia; Vaccine

Indexed keywords

ANTIBIOTIC AGENT; GAMMA INTERFERON; INFLUENZA VACCINE; OSELTAMIVIR; PENICILLIN G; PNEUMOCOCCUS VACCINE; TOLL LIKE RECEPTOR;

ACUTE OTITIS MEDIA; ANTIGEN DETECTION; BACTERIAL COLONIZATION; BACTERIAL SUPERINFECTION; BLOOD CULTURE; COMMUNITY ACQUIRED PNEUMONIA; CYTOKINE PRODUCTION; EARLY INTERVENTION; EPIDEMIC; HOSPITALIZATION; HUMAN; HUMAN METAPNEUMOVIRUS; IMMUNIZATION; INFECTION SENSITIVITY; INFLUENZA; INFLUENZA VIRUS; INFLUENZA VIRUS A H5N1; LOBAR PNEUMONIA; MIXED INFECTION; MORTALITY; NONHUMAN; PNEUMONIA; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA; VIRUS IDENTIFICATION; VIRUS PATHOGENESIS; VIRUS PNEUMONIA;

EID: 55149086971     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2.5.663     Document Type: Review

References (84)

1. Kilbourne ED. Influenza pandemics of the 20th century. Emerg. Inject. Dis. 12, 9-14 (2006).
2. Gust ID, Hampson AW, Lavanchy D. Planning for the next pandemic of influenza. Rev. Med. Virol. 11, 59-70 (2001).
3. Smil V. The next 50 years: fatal discontinuities. Pop. Dev. Rev. 31, 201-206 (2005).
4. Oxford JS, Lambkin R, Elliot A et al. Scientific lessons from the first influenza pandemic of the 20th Century. Vaccine 24, 6742-6746 (2006).
5. Uyeki TM. Global epidemiology of human infections with highly pathogenic avian influenza A (H5N1) viruses. Respirology 13(Suppl. 1), S2-S9 (2008).
6. Ortu G, Mounier-Jack S, Coker R. Pandemic influenza preparedness in Africa is a profound challenge for an already distressed region: analysis of national preparedness plans. Health Policy Plan. 23(3), 161-169 (2008).
7. Neuzil KM, Mellen BG, Wright PF et al. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N. Engl. J. Med. 342, 225-231 (2000).
8. Neuzil KM. Influenza: new insights into an old disease. Curr. Infect. Dis. Rep. 2, 224-230 (2000).
9. McCracken GH Jr. Etiology and treatment of pneumonia. Pediatr. Infect. Dis. J. 19, 373-377 (2000).
10. Taubenberger JK, Morens DM. 1918 Influenza: the mother of all pandemics. Emerg. Infect. Dis. 12, 15-22 (2006).
11. Uiprasertkul M, Kitphati R, Puthavathana P et al. Apoptosis and pathogenesis of avian influenza A (H5N1) virus in humans. Emerg. Infect. Dis. 13, 708-712 (2007).
12. de Jong MD, Simmons CP, Thanh TT et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 12, 1203-1207 (2006).
13. Brundage JF. Cases and deaths during influenza pandemics in the United States. Am. J. Prev. Med. 31, 252-256 (2006).
14. Kash JC, Tumpey TM, Proll SC et al. Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature 443, 578-581 (2006).
15. McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin. Microbiol. Rev. 19, 571-582 (2006).
16. Peltola VT, Murti KG, McCullers JA. Influenza virus neuraminidase contributes to secondary bacterial pneumonia. J. Infect. Dis. 192, 249-257 (2005).
17. McCullers JA, Rehg JE. Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J. Infect. Dis. 186, 341-350 (2002).
18. Peltola VT, McCullers JA. Respiratory viruses predisposing to bacterial infections: role of neuraminidase. Pediatr. Infect. Dis. J. 23, S87-S97 (2004).
19. LeVine AM, Koeningsknecht V, Stark JM. Decreased pulmonary clearance of S. pneumoniae following influenza A infection in mice. J. Virol. Methods 94, 173-186 (2001).
20. Plotkowski MC, Puchelle E, Beck G et al. Adherence of type 1 Streptococcus pneumoniae to tracheal epithelium of mice infected with influenza A/PR8 virus. Am. Rev. Respir. Dis. 134, 1040-1044 (1986).
21. Cundell DR, Gerard NP, Gerard C et al. Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Nature 377, 435-438 (1995).
22. van der Sluijs KF, van Elden LJ, Nijhuis M et al. Involvement of the platelet-activating factor receptor in host defense against Streptococcus pneumoniae during postinfluenza pneumonia. Am. J. Physiol. Lung Cell Mol. Physiol. 290, L194-L199 (2006).
23. McCullers JA, Iverson AR, McKeon R et al. The platelet activating factor receptor is not required for exacerbation of bacterial pneumonia following influenza. Scand. J. Infect. Dis. 40, 11-17 (2008).
24. McCullers JA, Bartmess KC. Role of neuraminidase in lethal synergism between influenza virus and i Streptococcus pneumoniae. J. Infect. Dis. 187, 1000-1009 (2003).
25. Tong HH, McIver MA, Fisher LM et al. Effect of lacto-N-neotetraose, asialoganglioside-GM1 and neuraminidase on adherence of otitis media-associated serotypes of Streptococcus pneumoniae to chinchilla tracheal epithelium. Microb. Pathog. 26, 111-119 (1999).
26. Dessing MC, van der Sluijs KF, Florquin S et al. Toll-like receptor 2 does not contribute to host response during postinfluenza pneumococcal pneumonia. Am. J. Respir. Cell Mol. Biol. 36, 609-614 (2007).
27. Seki M, Yanagihara K, Higashiyama Y et al. Immunokinetics in severe pneumonia due to influenza virus and bacteria coinfection in mice. Eur. Respir. J. 24, 143-149 (2004).
28. Didierlaurent A, Goulding J, Patel S et al. Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection. J. Exp. Med. 205, 323-329 (2008).
29. Sun K, Metzger DW. Inhibition of pulmonary antibacterial defense by IFN-γ during recovery from influenza infection. Nat. Med. 14, 558-564 (2008).
30. Colamussi ML, White MR, Crouch E et al. Influenza A virus accelerates neutrophil apoptosis and markedly potentiates apoptotic effects of bacteria. Blood 93, 2395-2403 (1999).
31. Abramson JS, Giebink GS, Quie PG. Influenza A virus-induced polymorphonuclear leukocyte dysfunction in the pathogenesis of experimental pneumococcal otitis media. Infect. Immun. 36, 289-296 (1982).
32. Nickerson CL, Jakab GJ. Pulmonary antibacterial defenses during mild and severe influenza virus infection. Infect. Immun. 58, 2809-2814 (1990).
33. McNamee LA, Harmsen AG. Both influenza-induced neutrophil dysfunction and neutrophil-independent mechanisms contribute to increased susceptibility to a secondary Streptococcus pneumoniae infection. Infect. Immun. 74, 6707-6721 (2006).
34. Grabowska K, Hogberg L, Penttinen P et al. Occurrence of invasive pneumococcal disease and number of excess cases due to influenza. BMC Infect. Dis. 6, 58 (2006).
35. Smitherman HF, Caviness AC, Macias CG. Retrospective review of serious bacterial infections in infants who are 0 to 36 months of age and have influenza A infection. Pediatrics 115, 710-718 (2005).
36. Mulholland K. Childhood pneumonia mortality - a permanent global emergency. Lancet 370, 285-289 (2007).
37. Klugman KP, Madhi SA, Albrich W. Novel approaches to the diagnosis of Streptococcus pneumoniae as a cause of community acquired pneumonia. Clin. Infect. Dis. (2008) (In Press).
38. van den Hoogen BG, de Jong JC, Groen J et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat. Med. 7, 719-724 (2001).
39. Fry AM, Lu X, Chittaganpitch M et al. Human bocavirus: a novel parvovirus epidemiologically associated with pneumonia requiring hospitalization in Thailand. J. Infect. Dis. 195, 1038-1045 (2007).
40. Choi EH, Lee HJ, Kim SJ et al. The association of newly identified respiratory viruses with lower respiratory tract infections in Korean children, 2000-2005. Clin. Infect. Dis. 43, 585-592 (2006).
41. Jennings LC, Anderson TP, Beynon KA et al. Incidence and characteristics of viral community-acquired pneumonia in adults. Thorax 63, 42-48 (2008).
42. Angeles Marcos M, Camps M, Pumarola T et al. The role of viruses in the aetiology of community-acquired pneumonia in adults. Antivir. Ther. 11, 351-359 (2006).
43. Kahn JS. Newly discovered respiratory viruses: significance and implications. Curr. Opin. Pharmacol. 7(5), 478-483 (2007).
44. Hall CB, Powell KR, Schnabel KC et al. Risk of secondary bacterial infection in infants hospitalized with respiratory syncytial viral infection. J. Pediatr. 113, 266-271 (1988).
45. Garcia-Vazquez E, Marcos MA, Mensa J et al. Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system. Arch. Intern. Med. 164, 1807-1811 (2004).
46. Heikkinen T, Thint M, Chonmaitree T. Prevalence of various respiratory viruses in the middle ear during acute otitis media. N. Engl. J. Med. 340, 260-264 (1999).
47. Giebink GS, Wright PF. Different virulence of influenza A virus strains and susceptibility to pneumococcal otitis media in chinchillas. Infect. Immun. 41, 913-920 (1983).
48. Giebink GS. Otitis media: the chinchilla model. Microb. Drug Resist. 5, 57-72 (1999).
49. Madhi SA, Klugman KP. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat. Med. 10, 811-813 (2004).
50. Madhi SA, Kuwanda L, Cutland C et al. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Clin. Infect. Dis. 40, 1511-1518 (2005).
51. Roson B, Fernandez-Sabe N, Carratala J et al. Contribution of a urinary antigen assay (Binax NOW) to the early diagnosis of pneumococcal pneumonia. Clin. Infect. Dis. 38, 222-226 (2004).
52. Ishida T, Hashimoto T, Arita M et al. A 3-year prospective study of a urinary antigen-detection test for Streptococcus pneumoniae in community-acquired pneumonia: utility and clinical impact on the reported etiology. J. Infect. Chemother. 10, 359-363 (2004).
53. Adegbola RA, Obaro SK, Biney E et al. Evaluation of Binax NOW Streptococcus pneumoniae urinary antigen test in children in a community with a high carriage rate of pneumococcus. Pediatr. Infect. Dis. J. 20, 718-719 (2001).
54. Dowell SF, Garman RL, Liu G et al. Evaluation of Binax NOW, an assay for the detection of pneumococcal antigen in urine samples, performed among pediatric patients. Clin. Infect. Dis. 32, 824-825 (2001).
55. Juven T, Mertsola J, Waris M et al. Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr. Infect. Dis. J. 19, 293-298 (2000).
56. Korppi M, Leinonen M, Koskela M et al. Bacterial coinfection in children hospitalized with respiratory syncytial virus infections. Pediatr. Infect. Dis. J. 8, 687-692 (1989).
57. Heiskanen-Kosma T, Korppi M, Jokinen C et al. Etiology of childhood pneumonia: serologic results of a prospective, population-based study. Pediatr. Infect. Dis. J. 17, 986-991 (1998).
58. Michelow IC, Lozano J, Olsen K et al. Diagnosis of Streptococcus pneumoniae lower respiratory infection in hospitalized children by culture, polymerase chain reaction, serological testing, and urinary antigen detection. Clin. Infect. Dis. 34, E1-E11 (2002).
59. Wubbel L, Muniz L, Ahmed A et al. Etiology and treatment of community-acquired pneumonia in ambulatory children. Pediatr. Infect. Dis. J. 18, 98-104 (1999).
60. Kim PE, Musher DM, Glezen WP et al. Association of invasive pneumococcal disease with season, atmospheric conditions, air pollution, and the isolation of respiratory viruses. Clin. Infect. Dis. 22, 100-106 (1996).
61. Talbot TR, Poehling KA, Hartert TV et al. Seasonality of invasive pneumococcal disease: temporal relation to documented influenza and respiratory syncytial viral circulation. Am. J. Med. 118, 285-291 (2005).
62. O'Brien KL, Walters MI, Sellman J et al. Severe pneumococcal pneumonia in previously healthy children: the role of preceding influenza infection. Clin. Infect. Dis. 30, 784-789 (2000).
63. de Roux A, Ewig S, Garcia E et al. Mixed community-acquired pneumonia in hospitalised patients. Eur. Respir. J. 27, 795-800 (2006).
64. Mills CE, Robins JM, Lipsitch M. Transmissibility of 1918 pandemic influenza. Nature 432, 904-906 (2004).
65. Brundage JF. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect. Dis. 6, 303-312 (2006).
66. Roberston L, Caley JP, Moore J. Importance of Staphylococcus aureus in pneumonia in the 1957 epidemic of influenza A. Lancet 2, 233-236 (1958).
67. Guarner J, Paddock CD, Shieh WJ et al. Histopathologic and immunohistochemical features of fatal influenza virus infection in children during the 2003-2004 season. Clin. Infect. Dis. 43, 132-140 (2006).
68. Anonymous. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. MMWR Morb. Mortal. Wkly Rep. 54, 893-897 (2005).
69. McAuley JL, Hornung F, Boyd KL et al. Expression of the 1918 influenza A virus PB1-F2 enhances the pathogenesis of viral and secondary bacterial pneumonia. Cell Host Microbe 2, 240-249 (2007).
70. Anonymous. Epidemiology of WHO-confirmed human cases of avian influenza A(H5N1) infection. Wkly Epidemiol. Rec. 81, 249-257 (2006).
71. Klugman KP, Cutts F, Adegbola RA et al. Meta-analysis of the efficacy of conjugate vaccine against invasive pneumococcal disease. In: Pneumococcal vaccines: The Impact of Conjugate Vaccine. Siber GR, Klugman KP, Mäkelä HP (Eds). ASM Press, Herndon, VA, USA 317-326 (2008).
72. Madhi SA, Ramasamy N, Bessellar TG et al. Lower respiratory tract infections associated with influenza A and B viruses in an area with a high prevalence of pediatric human immunodeficiency type 1 infection. Pediatr. Infect. Dis. J. 21, 291-297 (2002).
73. Madhi SA, Adrian P, Kuwanda L et al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine 25, 2451-2457 (2007).
74. Grijalva CG, Nuorti JP, Arbogast PG et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369, 1179-1186 (2007).
75. Black S, Shinefield H, Fireman B et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J. 19, 187-195 (2000).
76. Michelow IC, Olsen K, Lozano J et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics 113, 701-707 (2004).
77. Shafinoori S, Ginocchio CC, Greenberg AJ et al. Impact of pneumococcal conjugate vaccine and the severity of winter influenza-like illnesses on invasive pneumococcal infections in children and adults. Pediatr. Infect. Dis. J. 24, 10-16 (2005).
78. Dowell SF, Kupronis BA, Zell ER et al. Mortality from pneumonia in children in the United States, 1939 through 1996. N. Engl. J. Med. 342, 1399-1407 (2000).
79. Gross PA, Hermogenes AW, Sacks HS et al. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann. Intern. Med. 123, 518-527 (1995).
80. Manzoli L, Schioppa F, Boccia A et al. The efficacy of influenza vaccine for healthy children: a meta-analysis evaluating potential sources of variation in efficacy estimates including study quality. Pediatr. Infect. Dis. J. 26, 97-106 (2007).
81. McCullers JA. Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza. J. Infect. Dis. 190, 519-526 (2004).
82. Oxford J. Oseltamivir in the management of influenza. Expert Opin. Pharmacother. 6, 2493-2500 (2005).
83. Thomas JK, Noppenberger J. Avian influenza: a review. Am. J. Health Syst. Pharm. 64, 149-165 (2007).
84. van der Sluijs KF, van Elden LJ, Nijhuis M et al. IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection. J. Immunol. 172, 7603-7609 (2004).